Also known as: MASLD
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
A two-step FIB-4 plus VCTE approach effectively stratifies liver fibrosis and liver-related event risk in type 2 diabetes with MASLD. Prevalence of MASLD was 71.3% and significant fibrosis 21.1% in older outpatients.
Researchers have discovered that vitamin B3 (niacin) can effectively target microRNA-93, a key genetic driver of fatty liver disease. The study shows niacin reduces miR-93 levels and increases SIRT1 activity, restoring normal fat-processing pathways in the liver. This finding suggests a widely available vitamin could become a new treatment for metabolic-associated fatty liver disease affecting 30% of people globally.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07798518 |
FIB-4 Index, Sleep Apnea Severity, and Nocturnal Hypoxemia |
COMPLETED |
